Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review

被引：37

作者：

Apalla, Zoe ^{[1
]}

Papageorgiou, Chryssoula ^{[1
]}

Lallas, Aimilios ^{[2
]}

Delli, Florentina ^{[3
]}

Fotiadou, Christina ^{[1
]}

Kemanetzi, Christina ^{[1
]}

Lazaridou, Elizabeth ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, Sch Med, Dermatol Dept 2, Anatolis 5, Thessaloniki 55535, Greece

[2] Aristotle Univ Thessaloniki, Sch Med, Dermatol Dept 1, Thessaloniki, Greece

[3] Hippokratio Gen Hosp Thessaloniki, State Dermatol Dept, Thessaloniki, Greece

来源：

DERMATOLOGY PRACTICAL & CONCEPTUAL | 2021年 / 11卷 / 01期

关键词：

immune checkpoint inhibitors; skin toxicity; adverse effects; nivolumab; pembrolizumab; ipilimumab; METASTATIC MELANOMA; NIVOLUMAB THERAPY; IPILIMUMAB; PSORIASIS; MANAGEMENT; VITILIGO; PATIENT; IMMUNOTHERAPY; ASSOCIATION; TOXICITIES;

D O I：

10.5826/dpc.1101a155

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Immune checkpoints assist with self-tolerance and minimize collateral tissue damage when immune responses are activated. Although immune checkpoint inhibitors (CPIs) are characterized by a favorable risk/benefit ratio, immune checkpoint blockade has been associated with a new subset of autoimmunelike toxicities, named immune-related adverse events (irAEs). Dermatologic reactions are among the most prevalent irAEs triggered by CPIs. In a majority of cases they are self-limiting and readily manageable. However, it is not uncommon that they result in severe skin involvement and impairment of patients' quality of life. Awareness of the spectrum of cutaneous irAEs is mandatory for every clinician involved in the management of oncologic patients. The role of the dermatologists is essential because early recognition and appropriate management of skin toxicity may prevent dose modifications and discontinuation of CPIs. The latter is particularly relevant, considering that recent data suggest favorable oncologic response in patients developing irAEs.

引用

页数：11

共 67 条

[1] Drug-Associated Dermatomyositis Following Ipilimumab Therapy A Novel Immune-Mediated Adverse Event Associated With Cytotoxic T-Lymphocyte Antigen 4 Blockade [J].

Ali, Shirwa Sheik ;

Goddard, Allison L. ;

Luke, Jason J. ;

Donahue, Hilary ;

Todd, Derrick J. ;

Werchniak, Andrew ;

Vleugels, Ruth Ann .

JAMA DERMATOLOGY, 2015, 151 (02) :195-199

[2] Immunotherapy-mediated dermatological adverse events: the urgent need for a common, clinically meaningful, management strategy [J].

Apalla, Zoe ;

Sibaud, Vincent .

SUPPORTIVE CARE IN CANCER, 2020, 28 (12) :5597-5599

[3] Management of immune checkpoint inhibitor-induced bullous pemphigoid [J].

Apalla, Zoe ;

Lallas, Aimilios ;

Delli, Florentina ;

Lazaridou, Elizabeth ;

Papalampou, Stavroula ;

Apostolidou, Stavroula ;

Gerochristou, Maria ;

Rigopoulos, Dimitrios ;

Stratigos, Alexandros ;

Nikolaou, Vassiliki .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) :540-543

[4] Comment on "Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes'' [J].

Apalla, Zoe ;

Lazaridou, Elizabeth ;

Lallas, Aimilios .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) :E249-E249

[5] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[6] Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor [J].

Belum, V. R. ;

Benhuri, B. ;

Postow, M. A. ;

Hellmann, M. D. ;

Lesokhin, A. M. ;

Segal, N. H. ;

Motzer, R. J. ;

Wu, S. ;

Busam, K. J. ;

Wolchok, J. D. ;

Lacouture, M. E. .

EUROPEAN JOURNAL OF CANCER, 2016, 60 :12-25

[7]

Birnbaum Mathew R, 2017, JAAD Case Rep, V3, P208, DOI 10.1016/j.jdcr.2017.02.015

[8] Anti-PD1-induced psoriasis: a study of 21 patients [J].

Bonigen, J. ;

Raynaud-Donzel, C. ;

Hureaux, J. ;

Kramkimel, N. ;

Blom, A. ;

Jeudy, G. ;

Breton, A. L. ;

Hubiche, T. ;

Bedane, C. ;

Legoupil, D. ;

Pham-Ledard, A. ;

Charles, J. ;

Perol, M. ;

Gerard, E. ;

Combemale, P. ;

Bonnet, D. ;

Sigal, M. L. ;

Mahe, E. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (05) :e254-e257

[9] Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer [J].

Bousquet, Emilie ;

Zarbo, Allison ;

Tournier, Emilie ;

Chevreau, Christine ;

Mazieres, Julien ;

Lacouture, Mario E. ;

Sibaud, Vincent .

ACTA DERMATO-VENEREOLOGICA, 2017, 97 (04) :539-540

[10] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

← 1 2 3 4 5 6 7 →